Skin Disease in 37 Lithium-Battery Cathode-Material Workers

November 11, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: What can this study tell workers, families and occupational-health teams—and what would go beyond the evidence? This review keeps every number attached to its population, denominator, comparator and timepoint.

Study snapshot

Study element	Reported detail
Population	Thirty-seven workers with a history of skin disease recruited from two Korean lithium-ion battery cathode-active-material manufacturers.
Design	Descriptive case series using onsite investigations, semi-structured interviews and workplace observation.
Comparator	Symptom patterns by affected area, workday versus holiday timing and worker experience; there was no unaffected control cohort.
Timepoint	One investigation of prior and current symptom histories; no prospective follow-up period was reported.
Key result	Hands and forearms were affected in 67.6%; itching accounted for 27.5% of reported symptoms, erythema 20.3% and chemical burns 15.9%. Symptoms tended to worsen on workdays and improve during holidays.
Funding/conflict context	The PubMed grant record lists the Occupational Safety and Health Research Institute and Korea Occupational Safety and Health Agency, including project 2023-OSHRI-738.

What was actually measured?

Hands and forearms were affected in 67.6%; itching accounted for 27.5% of reported symptoms, erythema 20.3% and chemical burns 15.9%. Symptoms tended to worsen on workdays and improve during holidays.

A selected symptomatic series is best for describing patterns and generating controls, not calculating incidence. Chemical burns, irritant reactions and allergic dermatitis should not be collapsed into one diagnosis.

The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.

What the result does not prove

Only symptomatic volunteers were recruited, symptoms were not all clinician-confirmed and percentages describe reports within a selected case series, not prevalence among the full workforce.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.

Exposure detail matters more than the job label

Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve on days away or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredient information and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes